Ginkgo Bioworks Holdings, Inc. (DNA) Research
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
Market snapshot
- Symbol
- DNA
- Price
- $9.17
- Day change
- +7.25%
- Market cap
- $599.0M
- P/E ratio
- -1.79x
- 52-week range
- 5.37-17.58
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $7.84
Recent news
- TelevisaUnivision Bets Its Telenovela DNA Can Win The Microdrama Race
TelevisaUnivision is moving aggressively to turn its microdrama platform into a new growth engine, betting that the melodramatic storytelling that powered decades of telenovelas can be reshaped for mobile-first audiences in one- to two-minute vertical episodes.
Peer companies
Recent insider activity
- HENRY CHRISTIAN O — A-Award (25000 shares) on 2026-06-11
- Fubini Ross — A-Award (25000 shares) on 2026-06-11
- Kosuri Sri — A-Award (25000 shares) on 2026-06-11
- SLOAN HARRY — A-Award (25000 shares) on 2026-06-11
- Coen Steven P. — M-Exempt (156 shares) on 2026-05-21
Open Ginkgo Bioworks Holdings, Inc. (DNA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.